Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Pulmonary Arterial Hypertension Market to Grow 4.95% by 2021 - Key Players are Bayer AG, Gilead Sciences & Pfizer - Research and Markets

Research and Markets
Posted on: 26 Aug 16

Research and Markets has announced the addition of the "Global Pulmonary Arterial Hypertension (PAH) Market (By Drug Class, By Region, By Country): Opportunities and Forecasts (2016-2021)" report to their offering.

The Global Pulmonary Arterial Hypertension market is projected to exhibit a CAGR of over 4.95% during 2016-2021.

The report suggests that rising development of pipeline drugs in PAH combined with the growing awareness of the disease majorly in developed countries has resulted in the growth of PAH market. Also, the market for Pulmonary Arterial Hypertension (PAH) is growing moderately due to newer launches of pipeline drugs that target different pathways to suppress the symptoms of the disease. Early diagnosis of the disease has played a pivotal role in number of patients undergoing treatment.

While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population.

North America region remains the major market followed by Europe in the actual period. In the forecast period, APAC region will witness strong growth driven by countries such as India and China.

Companies Mentioned:

  • Actelion Pharmaceuticals Ltd.
  • Arena Pharmaceuticals Inc.
  • Bayer AG
  • Gilead sciences
  • GlaxoSmithKline plc
  • Merck & Co. Inc
  • Pfizer Inc.
  • Reata Pharmaceuticals Inc.
  • SteadyMed Ltd.
  • United Therapeutics Corporation

Key Topics Covered:

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Global PAH Market: An Overview

5. North America PAH Market: An Overview

6. Europe PAH Market: An Overview

7. APAC PAH Market: An Overview

8. Latin America PAH Market: An Overview

9. MEA PAH Market: An Overview

10. Market Dynamics

11. Policy and Regulatory Landscape

12. M&A and Licensing Route to the PAH Market

13. SWOT Analysis

14. Porter Five Force Model

15. Competitive Market Share Analysis

16. Competitive landscape

17. Company Profiles

For more information about this report visit

Related Topics: Cardiovascular Drugs

View source version on

Business Wire

Last updated on: 26/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.